Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Citius Oncology, Inc.NASDAQ: CTOR

Cost of Revenue · Q2 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $328.88K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.12M.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $328.88K or moves back toward the trailing-twelve-month quarterly average of $279.52K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$328.88K-58.3% QoQ
Last fiscal yearSep 2025
$0— YoY
LTMMar 2026
$1.12M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 cost of revenue of $1.12M is the 6th highest of the 10 companies compared; the peer median is $1.39M.
  • Cost of revenue amounts to 19.9% of revenue for CTOR, versus a peer median of 51.9%.
CTOR Competitors Peer median
Cost of Revenue for CTOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OWLTOwlet, Inc.LTM Mar 2026$52.61M +30.6%+4.4%49.1%
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M -62.0%-2.1%515.8%
LNSRLENSAR, Inc.LTM Mar 2026$31.55M +5.2%+26.7%54.7%
SCLXScilex Holding CompanyLTM Mar 2026$15.25M +7.1%+12.1%45.0%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$1.39M -86.2%—120.9%
CTORCitius Oncology, Inc.LTM Mar 2026$1.12M ——19.9%
VORVor Biopharma Inc.LTM Mar 2026$28K -98.4%——
FBRXForte Biosciences, Inc.LTM Mar 2026$6K -86.0%——
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
ACTUActuate Therapeutics IncLTM Mar 2026$0 ———
Peer median (excluding CTOR) $1.39M-74.0%+8.3%51.9%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.